Oxford BioDynamics Plc (LON:OBD – Get Free Report)’s share price dropped 3.2% during trading on Monday . The company traded as low as GBX 1.20 ($0.02) and last traded at GBX 1.20 ($0.02). Approximately 354,030 shares traded hands during trading, a decline of 81% from the average daily volume of 1,843,727 shares. The stock had previously closed at GBX 1.24 ($0.02).
Oxford BioDynamics Stock Down 0.8 %
The company has a market capitalization of £3.77 million, a PE ratio of -19.25 and a beta of 0.42. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The business’s 50 day simple moving average is GBX 2.34 and its 200 day simple moving average is GBX 5.57.
Insider Buying and Selling at Oxford BioDynamics
In other Oxford BioDynamics news, insider David Holbrook bought 49,653 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average cost of GBX 1 ($0.01) per share, with a total value of £496.53 ($628.28). 16.78% of the stock is owned by corporate insiders.
Oxford BioDynamics Company Profile
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients.
See Also
- Five stocks we like better than Oxford BioDynamics
- What does consumer price index measure?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- How to Calculate Inflation Rate
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.